An Uphill Battle Against The
2024-07-17
These Medicines in the latest breakthrough of clinical progress in pancreatic cancer therapy, rekindled people for "king conquer cancer" the grand goal of hope. The company recently announced its extensive RAS inhibitorsRAS inhibitors of RMC - 6236-1 b phase of clinical trial data. Results show that the RMC - 6236 as the second line monotherapy with KRAS G12X mutations in patients with pancreatic ductal adenocarcinoma (PDAC), made remarkable curative effect, the patient's median progression-free surial (PFS) reached 8.1 months, disease control rates (DCR) up to nearly 90%. This exciting data, prompted Revolution Medicines actively preparing for PDAC second-line therapy in patients with global randomized clinical phase 3 trials, in order to compare the RMC - 6236 and the differences of traditional chemotherapy in the treatment effect.
KRAS and their associated signaling pathways have been the focus of cancer research, because of KRAS mutations play a key role in a variety of malignant tumors, including 90% of pancreatic cancer, 30-50% of colorectal cancer and 15-20% of non-small cell lung cancer. On the market at present already approved KRAS inhibitorsKRAS inhibitors, such as Sotorasib and Adagrasib, although made a certain curative effect in clinic, but the overall effect of limited, remission rate in just 30-40%, progression-free surial only about six months.
In stark contrast, Revolution Medicines' RMC-6236 has shown more promising results in second-line treatment of PDAC patients. The biotech company adopts unique technical strategy and the latest clinical trial data, caused the extensive concern of investors and industry experts and look forward to.
As the Revolution Medicines will launch phase 3 clinical trials around the world, people will pay close attention to the biotechnology company in "king conquer cancer" on the path of the latest progress. If you can succeed, this is expected to completely change the status quo of medical treatment of pancreatic cancer patients bring new hope and vitality.
更多内容，请访问原始网站
文中所述内容并不反映新药情报库及其所属公司任何意见及观点，如有版权侵扰或错误之处，请及时联系我们，我们会在24小时内配合处理。
来和芽仔聊天吧
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。